JP7598195B2 - 肥満及び関連する障害の予防及び治療のための化合物 - Google Patents

肥満及び関連する障害の予防及び治療のための化合物 Download PDF

Info

Publication number
JP7598195B2
JP7598195B2 JP2021551942A JP2021551942A JP7598195B2 JP 7598195 B2 JP7598195 B2 JP 7598195B2 JP 2021551942 A JP2021551942 A JP 2021551942A JP 2021551942 A JP2021551942 A JP 2021551942A JP 7598195 B2 JP7598195 B2 JP 7598195B2
Authority
JP
Japan
Prior art keywords
methyl
subject
compound
pharmaceutical composition
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021551942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523792A (ja
JP2022523792A5 (https=
Inventor
エ ヴィラフランカ，ヘスース
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abrexa Pharmaceuticals Inc
Original Assignee
Abrexa Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abrexa Pharmaceuticals Inc filed Critical Abrexa Pharmaceuticals Inc
Publication of JP2022523792A publication Critical patent/JP2022523792A/ja
Publication of JP2022523792A5 publication Critical patent/JP2022523792A5/ja
Application granted granted Critical
Publication of JP7598195B2 publication Critical patent/JP7598195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021551942A 2019-03-01 2020-03-02 肥満及び関連する障害の予防及び治療のための化合物 Active JP7598195B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962812314P 2019-03-01 2019-03-01
US62/812,314 2019-03-01
PCT/US2020/020707 WO2020180821A1 (en) 2019-03-01 2020-03-02 Compounds for prevention and treatment of obesity and related disorders

Publications (3)

Publication Number Publication Date
JP2022523792A JP2022523792A (ja) 2022-04-26
JP2022523792A5 JP2022523792A5 (https=) 2023-03-07
JP7598195B2 true JP7598195B2 (ja) 2024-12-11

Family

ID=72338080

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021551942A Active JP7598195B2 (ja) 2019-03-01 2020-03-02 肥満及び関連する障害の予防及び治療のための化合物

Country Status (7)

Country Link
US (1) US12357596B2 (https=)
EP (1) EP3931179B1 (https=)
JP (1) JP7598195B2 (https=)
CN (1) CN114072376B (https=)
CA (1) CA3132318A1 (https=)
ES (1) ES3059224T3 (https=)
WO (1) WO2020180821A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024249415A1 (en) * 2023-05-26 2024-12-05 Abrexa Pharmaceuticals, Inc. Compounds for use in organ preservation and organ transplantation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100305181A1 (en) 2007-10-15 2010-12-02 Schubert David R Methods for treating a variety of diseases and conditions, and compounds useful therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017540A (en) * 1968-03-04 1977-04-12 The Upjohn Company Method of use, composition, and compounds
US20100004302A1 (en) * 2003-04-29 2010-01-07 Connie Erickson-Miller Methods for Treating Degenerative Diseases/Injuries
US20070238700A1 (en) * 2006-04-10 2007-10-11 Winzenberg Kevin N N-phenyl-1,1,1-trifluoromethanesulfonamide hydrazone derivative compounds and their usage in controlling parasites
WO2017112701A1 (en) * 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100305181A1 (en) 2007-10-15 2010-12-02 Schubert David R Methods for treating a variety of diseases and conditions, and compounds useful therefor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
APPETITE，2018年，128，pp.44-49
Diabetes Obes Metab.，2017年，19，pp.1242-1251

Also Published As

Publication number Publication date
EP3931179A1 (en) 2022-01-05
CN114072376A (zh) 2022-02-18
WO2020180821A1 (en) 2020-09-10
ES3059224T3 (en) 2026-03-19
CA3132318A1 (en) 2020-09-10
EP3931179C0 (en) 2025-12-10
CN114072376B (zh) 2024-12-20
US12357596B2 (en) 2025-07-15
EP3931179A4 (en) 2022-11-30
US20220133657A1 (en) 2022-05-05
JP2022523792A (ja) 2022-04-26
EP3931179B1 (en) 2025-12-10

Similar Documents

Publication Publication Date Title
AU2014340182B2 (en) Cromolyn derivatives and related methods of imaging and treatment
US20100168112A1 (en) 2-Substituted and 4-substituted aryl nitrone compounds
CN106999462B (zh) 包含选择性s1p1受体激动剂的药物组合物
EP3931178B1 (en) Compounds for prevention and treatment of post-operative cognitive dysfunction
CA2685380A1 (en) Inhibitors of acetyl-coa carboxylase for treatment of neuronal hypometabolism
JP7740810B2 (ja) 呼吸困難に起因する集中治療後の認知機能障害及び認知障害の予防及び治療のための化合物
RU2693627C2 (ru) Комбинации эдаравона для лечения ишемических повреждений мозга
JP7598195B2 (ja) 肥満及び関連する障害の予防及び治療のための化合物
JP6377620B2 (ja) グルコース取り込みを改善するための組成物および方法
CA3130735A1 (en) Inositol phosphate compounds for use in increasing tissular perfusion
JP7033317B2 (ja) 白内障の予防剤、治療剤、およびこれらを製造するためのｈａｔ阻害剤の使用
BRPI0710209A2 (pt) uso de derivados de estrobilurina, medicamento, e, processo para a preparação de um medicamento
WO2024249415A1 (en) Compounds for use in organ preservation and organ transplantation
US11938104B1 (en) Compositions and methods for prevention and treatment of coronavirus and related disorders
RU2838908C2 (ru) Соединения инозитолфосфата для применения для увеличения тканевой перфузии
HK40089435A (zh) 预防和治疗重症监护後认知功能障碍和呼吸窘迫致认知功能障碍的化合物
JP2023538673A (ja) 出血および血管系不安定症の予防および処置用化合物
EA043008B1 (ru) Комбинации эдаравона для лечения ишемических повреждений мозга
JPWO2003090735A1 (ja) ヒドロキサム酸化合物を有効成分として含有する炎症性腸疾患治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240813

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241030

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241128

R150 Certificate of patent or registration of utility model

Ref document number: 7598195

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150